Evidence map›Paper›PMID 36966239›Full record

ArticleAnnals of hematology2023

Real-life experience of secondary prophylaxis with DOACs in splanchnic venous thrombosis during COVID-19 pandemic.

Luca Guarnera, Elisa Buzzatti, Fabrizio Bonanni, Giovangiacinto Paterno, Antonella Riccitelli, Vittorio Forte, Adriano Venditti, Maria Ilaria Del Principe

Open access · bronzeAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Luca GuarneraHematology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Elisa BuzzattiHematology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Fabrizio BonanniHematology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Giovangiacinto PaternoHematology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Antonella RiccitelliHematology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Vittorio ForteHematology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Adriano VendittiHematology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy. adriano.venditti@uniroma2.it.ORCID 0000-0002-0245-0553
Maria Ilaria Del PrincipeHematology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
University of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Venous ThromboembolismVenous ThrombosisAnticoagulantsHumansPandemicsSecondary PreventionAnticoagulants

Identifiers

PMID36966239
PMCPMC10039765
OpenAlexW4360943978

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.